Fig. 3: Anti-proliferative effect of 6-position-modified lenalidomide on multiple myeloma and 5q myelodysplastic syndromes.
From: Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
a Immunoblot analysis of IRF4 and c-Myc. MM1.S or H929 cells were treated with dimethylsulfoxide (DMSO), Po, Le, or lenalidomide derivatives for 72 h. The experiment was independently repeated thrice, with similar results. b Immunoblot analysis of RUNX1. Myelodysplastic syndrome (MDS)-L cells were treated with DMSO, Po, Le, or lenalidomide derivatives for 24 h. The experiment was repeated twice independently, with similar results. c Expression of SELP and ITGB3, which are upregulated in 5q MDS cells treated with lenalidomide. MDS-L cells were treated with DMSO, 10-µM Po, 10-µM Le, or 10-µM lenalidomide derivatives for 3 or 6 days, and mRNA expression was measured using quantitative RT-PCR. Relative mRNA expression was determined using the expression level following DMSO treatment. Error bars denote standard deviation (biological replicates; n = 3). d Dose–response curve of the anti-proliferative effect of 6-position-modified lenalidomides on MM cell lines. MM1.S and H929 cells were treated with DMSO, Po, Le, F-Le, or Cl-Le for 10 days, and cell viability was analysed using the CellTiter-Glo assay kit. Cell viability was expressed as the luminescence signal relative to the luminescence signal of DMSO, which was considered 100. Error bars denote standard deviation (biological replicates; n = 3). e Dose–response curve of anti-proliferative effect by 6-position-modified lenalidomides on 5q MDS cell line. MDS-L cells were treated with DMSO, Po, Le, F-Le, or Cl-Le for 12 days, and cell viability was analysed using the CellTiter-Glo assay kit. Cell viability was expressed as the luminescence signal relative to the luminescence signal of DMSO, which was considered 100. Error bars denote standard deviation (biological replicates; n = 4). f The half-maximal growth inhibition (GI50) and the maximal growth inhibition (GImax) values were calculated using the dose–response curve in (d, e). N/A means not applicable. Source data are provided as a Source data file.
